The impact of monocyte to HDL ratio and Prognostic Nutritional Index on survival in stage III colorectal cancer patients

Mehmet Salim Demir; Merve Yumak

Makale detayları

The impact of monocyte to HDL ratio and Prognostic Nutritional Index on survival in stage III colorectal cancer patients

Yazarlar:

Mehmet Salim Demir | Merve Yumak

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji

Dergi:

Journal of Health Sciences and Medicine Vol.8 Issue 5, pp.805-810

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001358391

pISSN:

2636-8579

Anahtar kelimeler:

Özet:

 Aims: This study explores how systemic inflammatory and nutritional indicators, specifically the monocyte-to-high-density lipoprotein ratio MHR and Prognostic Nutritional Index PNI, influence clinical outcomes in stage III colorectal cancer CRC patients. Methods: A retrospective review of 109 individuals was conducted. ROC curve analysis was employed to determine the optimal cut-off values of MHR and PNI for predicting mortality. Survival outcomes, including overall survival OS and disease-free survival DFS, were evaluated using Kaplan-Meier estimates and compared with log-rank tests. Cox regression was utilized to pinpoint factors independently associated with DFS. Results: The findings revealed significantly lower OS among patients not undergoing adjuvant chemotherapy 45.6 vs. 82.2 months; p0.002. Additionally, diminished MHR 0.37 and PNI 46.8 levels were linked to poorer OS p0.041 and p0.003, respectively. While low PNI was also associated with reduced DFS p0.021, MHR did not significantly impact DFS p0.42. Both MHR AUC: 0.643 and PNI AUC: 0.657 demonstrated moderate predictive capabilities for mortality. Importantly, perineural invasion surfaced as an independent negative prognostic factor for DFS HR: 2.36; p0.038. Conclusion: In conclusion, pre-treatment MHR and PNI values serve as accessible and low-cost indicators that may assist in prognostic stratification in stage III CRC management.

 Aims: This study explores how systemic inflammatory and nutritional indicators, specifically the monocyte-to-high-density lipoprotein ratio MHR and Prognostic Nutritional Index PNI, influence clinical outcomes in stage III colorectal cancer CRC patients. Methods: A retrospective review of 109 individuals was conducted. ROC curve analysis was employed to determine the optimal cut-off values of MHR and PNI for predicting mortality. Survival outcomes, including overall survival OS and disease-free survival DFS, were evaluated using Kaplan-Meier estimates and compared with log-rank tests. Cox regression was utilized to pinpoint factors independently associated with DFS. Results: The findings revealed significantly lower OS among patients not undergoing adjuvant chemotherapy 45.6 vs. 82.2 months; p0.002. Additionally, diminished MHR 0.37 and PNI 46.8 levels were linked to poorer OS p0.041 and p0.003, respectively. While low PNI was also associated with reduced DFS p0.021, MHR did not significantly impact DFS p0.42. Both MHR AUC: 0.643 and PNI AUC: 0.657 demonstrated moderate predictive capabilities for mortality. Importantly, perineural invasion surfaced as an independent negative prognostic factor for DFS HR: 2.36; p0.038. Conclusion: In conclusion, pre-treatment MHR and PNI values serve as accessible and low-cost indicators that may assist in prognostic stratification in stage III CRC management.

 Aims: This study explores how systemic inflammatory and nutritional indicators, specifically the monocyte-to-high-density lipoprotein ratio MHR and Prognostic Nutritional Index PNI, influence clinical outcomes in stage III colorectal cancer CRC patients. Methods: A retrospective review of 109 individuals was conducted. ROC curve analysis was employed to determine the optimal cut-off values of MHR and PNI for predicting mortality. Survival outcomes, including overall survival OS and disease-free survival DFS, were evaluated using Kaplan-Meier estimates and compared with log-rank tests. Cox regression was utilized to pinpoint factors independently associated with DFS. Results: The findings revealed significantly lower OS among patients not undergoing adjuvant chemotherapy 45.6 vs. 82.2 months; p0.002. Additionally, diminished MHR 0.37 and PNI 46.8 levels were linked to poorer OS p0.041 and p0.003, respectively. While low PNI was also associated with reduced DFS p0.021, MHR did not significantly impact DFS p0.42. Both MHR AUC: 0.643 and PNI AUC: 0.657 demonstrated moderate predictive capabilities for mortality. Importantly, perineural invasion surfaced as an independent negative prognostic factor for DFS HR: 2.36; p0.038. Conclusion: In conclusion, pre-treatment MHR and PNI values serve as accessible and low-cost indicators that may assist in prognostic stratification in stage III CRC management.

 Amaç: Bu çalışma, sistemik inflamasyon ve beslenme durumunu yansıtan biyobelirteçler olan monosityüksek yoğunluklu lipoprotein oranı MHR ile prognostik beslenme indeksi PNInin, evre III kolorektal kanser KRK hastalarında klinik sonuçlara olan etkisini değerlendirmeyi amaçlamaktadır. Yöntemler: Toplam 109 hastanın retrospektif olarak değerlendirildiği bu çalışmada, MHR ve PNI için optimal eşik değerler ROC eğrisi analizi ile belirlendi. Genel sağkalım OS ve hastalıksız sağkalım PFS Kaplan-Meier yöntemiyle analiz edildi ve log-rank testi ile karşılaştırmalar yapıldı. PFS ile ilişkili bağımsız prognostik faktörler çok değişkenli Cox regresyon analiziyle belirlendi. Bulgular: Adjuvan kemoterapi almayan hastalarda genel sağkalım anlamlı ölçüde daha düşüktü 45.6 aya karşı 82.2 ay; p0.002. Ayrıca, düşük MHR 0.37 ve düşük PNI 46.8 seviyeleri, daha kısa genel sağkalımla ilişkili bulundu p0.041 ve p0.003. Düşük PNI düzeyi aynı zamanda daha kötü hastalıksız sağkalım ile de anlamlı şekilde ilişkiliydi p0.021. MHR AUC: 0.643 ve PNI AUC: 0.657 mortaliteyi öngörmede orta düzeyde tahmin gücü sergiledi. Bununla birlikte, perinöral invazyon, hastalıksız sağkalım için bağımsız ve olumsuz bir prognostik faktör olarak saptandı HR: 2.36; p0.038. Sonuç: Tedavi öncesi MHR ve PNI değerleri, evre III kolorektal kanser hastalarında prognozun belirlenmesinde ve tedavi kararlarının yönlendirilmesinde kullanılabilecek, kolay erişilebilir ve düşük maliyetli biyobelirteçlerdir.

Makale detayları

The impact of monocyte to HDL ratio and Prognostic Nutritional Index on survival in stage III colorectal cancer patients

Yazarlar:

Mehmet Salim Demir | Merve Yumak

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji

Dergi:

Journal of Health Sciences and Medicine Vol.8 Issue 5, pp.805-810

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001358391

pISSN:

2636-8579

Monocyte-to-HDL ratio

Prognostic Nutritional Index

colorectal cancer

stage III

survival

prognostic markersMonosit-HDL oranı

Prognostik Beslenme İndeksi

kolorektal kanser

evre III

sağkalım

prognostik belirteçler

Sayı

Makale detayları

Yazarlar: Mehmet Salim Demir | Merve Yumak

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Klinik Onkoloji

Dergi: Journal of Health Sciences and Medicine Vol.8 Issue 5, pp.805-810

Belge Tipi: Makale

Yayın Tarihi: 9/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001358391

pISSN: 2636-8579

Sayı

Yazarlar:

Mehmet Salim Demir | Merve Yumak

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji

Dergi:

Journal of Health Sciences and Medicine Vol.8 Issue 5, pp.805-810

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001358391

pISSN:

2636-8579